NCT03289702View on ClinicalTrials.gov

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

November 9, 2018

Conditions
Muscle Spasticity
Interventions
DRUG

CORETOX®

Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

DRUG

BOTOX®

Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03289702 - CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3) | Biotech Hunter | Biotech Hunter